Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564155 | 1.00 | HTR1A (0.55) | HTR1AKDM1AMAOB | |
| SCHEMBL26634553 | 0.91 | HTR1A (0.62) | HTR1AMAOB | |
| SCHEMBL6970401 | 0.90 | HTR1A (0.64) | HTR1AKDM1AMAOB | |
| SCHEMBL829254 | 0.90 | HTR1A (0.64) | HTR1AMAOB | |
| SCHEMBL6964152 | 0.90 | HTR1A (0.64) | HTR1AKDM1AMAOB | |
| SCHEMBL7083797 | 0.89 | HTR1A (0.65) | HTR1AMAOB | |
| Hydrochloric Acid SCHEMBL829918 | 0.89 | HTR1A (0.62) | HTR1AMAOB | |
| Hydrochloric Acid SCHEMBL2558698 | 0.89 | HTR1A (0.62) | HTR1AMAOB | |
| Hydrochloric Acid SCHEMBL2557258 | 0.87 | HTR1A (0.63) | HTR1AMAOB | |
| SCHEMBL23164620 | 0.87 | HTR1A (0.67) | HTR1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456473-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-10-29 | — | — | US | claimed |
| US-20180104342-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-04-19 | — | — | US | claimed |
| CN-102421417-A | Lipid composition | ALNYLAM PHARMACEUTICALS INC | 2012-04-18 | — | — | CN | claimed |
| EP-2416760-A1 | LIPID COMPOSITIONS | Alnylam Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| WO-2010129709-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| EP-1277771-A2 | Living polymerisation process for the production of sequenced polymers using functional radical initiators | Atofina (FR) | 2003-01-22 | — | — | EP | claimed |
| EP-0911350-A1 | Fabrication process for copolymers of controlled architecture via the use of functional radical initiators in a living radical polymerisation, and initiator compositions and corresponding copolymers | ELF ATOCHEM S.A. (FR) | 1999-04-28 | — | — | EP | claimed |
| US-12023383-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-02 | — | — | US | disclosed |
| US-12023383-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-02 | — | — | US | disclosed |
| US-20240066129-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066129-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066129-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| CN-114524781-A | Lipid composition | 阿布特斯生物制药公司 | 2022-05-24 | — | — | CN | disclosed |
| WO-2010129709-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129709-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-1288236-A2 | Production process for copolymers with controlled architecture with the aid of functional radical initiators in a living radical polymerisation | Atofina (FR) | 2003-03-05 | — | — | EP | disclosed |
| EP-1277771-A2 | Living polymerisation process for the production of sequenced polymers using functional radical initiators | Atofina (FR) | 2003-01-22 | — | — | EP | disclosed |
| EP-0911350-A1 | Fabrication process for copolymers of controlled architecture via the use of functional radical initiators in a living radical polymerisation, and initiator compositions and corresponding copolymers | ELF ATOCHEM S.A. (FR) | 1999-04-28 | — | — | EP | disclosed |
| US-5318970-A | Cyclooxygenase, lipoxygenase inhibitors | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1994-06-07 | — | — | US | disclosed |
| EP-0549797-A1 | ISOXAZOLE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICINAL USE THEREOF | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1993-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104342-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | HTR1A 3997/4885KDM1A 4762/4885MAOB 3705/4885 |
| US-10456473-B2 | Lipid compositions | SGMS1, LIPA, SGMS2 | HTR1A 3997/4885KDM1A 4762/4885MAOB 3705/4885 |
| US-20240066129-A1 | LIPID COMPOSITIONS | SGMS1, SGMS2, LIPA | HTR1A 4268/4885KDM1A 4781/4885MAOB 3749/4885 |
| US-12023383-B2 | Lipid compositions | SGMS1, SGMS2, LIPA | HTR1A 4268/4885KDM1A 4781/4885MAOB 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.